Chemotherapy With or Without 9-ING-41 for Pancreatic Cancer (Actuate 1801) - Clinical Trial

What is the Purpose of this Study?


We are doing this study to find out if and investigational drug called 9-ING-41 (the study drug) is safe and effective for treating pancreatic cancer.

What is the Condition Being Studied?

Pancreatic Adenocarcinoma

Who Can Participate in the Study?

Key Eligibility

Adults ages 18+ who:
- Are diagnosed with metastatic pancreatic adenocarcinoma
- Have not received any previous cancer treatment

For more information about who can join this study, please contact the study team at 919-668-1861.

Age Group

What is Involved?


If you choose to join this study, you will:
- Be assigned to get either 9-ING-41 + standard chemotherapy or standard chemotherapy alone
- Get IV infusions of 9-ING-41 every week (if assigned)
- Get IV infusions of chemotherapy drugs nab-paclitaxel and gemcitabine about 3 times per month
- Give blood and urine samples
- Have regular CT or MRI scans

Study Details

Full Title
Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3?) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00112806
NCT: NCT03678883
Phase I/II
Enrollment Status
Open for Enrollment